Ascentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each

Bulletin Express

Jun 11

Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.

The transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.

Following this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.

No additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1121548855"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121548855\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121548855?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121548855","market":"us","top_or_hot":-1,"title":"Ascentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each","media":"Bulletin Express","content":"<p>Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.</p>\n<p>The transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.</p>\n<p>Following this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.</p>\n<p>No additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-11 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.</p>\n<p>The transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.</p>\n<p>Following this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.</p>\n<p>No additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药","start_time":0,"source_url":"","article_id":"1121548855","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121548855","pubTimestamp":1781185366,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药"},"translate_title":"亚盛医药：受讬人按每股33.37港元购买110,000股2022年受限制股份单位计划股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.\nThe transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.\nFollowing this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.\nNo additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}